HomeAuthorsPosts by Sam Atkinson

Sam Atkinson

SGX-LISTED COMPANIES

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge in profit for the third quarter ended May 31, 2026. This performance marks a decisive shift from a period of recovery toward a new phase of resilient growth in the...
Pharmaceutical

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the country grapples with a growing burden of non-communicable diseases (NCDs), particularly diabetes and chronic kidney disease. Recent estimates show that one-in-six Malaysians has diabetes, while one-in-seven is at risk of chronic...
spot_img

Keep exploring

SGX-LISTED COMPANIES

Will Singtel’s Rally Continue Or Slowdown In 2026?

A Year of Unprecedented Gains As of March 2026, Singapore Telecommunications Ltd (Singtel) has managed...
SGX-LISTED COMPANIES

The Assembly Place FY2025 – Singapore’s Fastest Growing Community Living Giant

4 Surprising Takeaways from Singapore’s Fastest-Growing Community Living Giant The landscape of urban residency is...
SGX-LISTED COMPANIES

Accounting Alchemy & The Radical Slim-Down At Tan Chong International FY2025

The 920% Surprise To the uninitiated, the 2025 annual results of Tan Chong International Limited...
SGX-LISTED COMPANIES

Thakral Corporation FY2025 Sees A S$174 Million Surge

Why Losing Influence in GemLife Was Thakral’s Strategic Masterstroke Sophisticated retail investors often find themselves...
SGX-LISTED COMPANIES

Tianjin Pharmaceutical Da Ren Tang Is Shrinking To Succeed In FY2025

How TJ DRT’s 33% Revenue "Loss" Fueled a 72% Margin Miracle and a Record...
SGX-LISTED COMPANIES

Sales Are Up, But Where’s The Cash? China Kangda Food FY2025

4 Surprising Takeaways from China Kangda’s 2025 Financials China Kangda Food Company Limited occupies a...
SGX-LISTED COMPANIES

The Strategy Keeping Camsing Healthcare Alive – FY2026

The Survival Pivot: 4 Lessons from a Retail Healthcare Turnaround Introduction: The narrative of the legacy...
SGX-LISTED COMPANIES

How Geopolitics & Administrative Faults Left Ouhua Energy Fighting For Air In FY2025

https://open.spotify.com/episode/2MRrUHNo4mAmqYqJhej1pr?si=3e230667e6cf4daf Introduction: The High-Stakes World of Energy The global energy sector is a theater of the...
SGX-LISTED COMPANIES

Why Concord New Energy Slashed Its Staff By 30% Despite The Green Boom In FY2025

https://open.spotify.com/episode/1410f2bEfJOeMrsTN7h0o5?si=3d3bfdb638864161 Introduction The global transition to renewable energy is frequently marketed as an unstoppable economic juggernaut,...
SGX-LISTED COMPANIES

Shangri-La Asia’s New Secret Brand Is Changing Luxury Travel Forever – FY2025

https://open.spotify.com/episode/47qSjuUFLJE9weFQMF1MbL?si=7156e1bb681a4c90 5 Surprising Shifts Redefining the Future of Luxury at Shangri-La The global travel industry is...
SGX-LISTED COMPANIES

Yunnan Energy Swaps Commodities For Green Infrastructure In FY2025

https://open.spotify.com/episode/7CLJDXt0eVhh2zP7bTs9zK?si=a562cf64ec304022 Yunnan Energy’s Strategic Retreat to Higher Ground In corporate strategy, as in viticulture, the most...
SGX-LISTED COMPANIES

How Koh Brothers Engineered An $18.6 Million Turnaround In FY2025

https://open.spotify.com/episode/0MR3rCI8pluQ2MExvdb3st?si=84a1d2c0be0e4fca A Tale of Two Financial Years In the unforgiving arena of Singapore’s built environment, a...
Load more

Latest articles

SGX-LISTED COMPANIES

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...
Pharmaceutical

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...
Pharmaceutical

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...
Pharmaceutical

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...